Johnson & Johnson’s Innovation LLC arm said Thursday it has reached agreements for 15 new collaborations across 3D printing, the microbiome and immunotherapy.
“These collaborations, which are focused on developing novel healthcare solutions in areas of high unmet need such as depression, cancer and diabetes, bring the total number of strategic transactions to more than 300 since the establishment of Johnson & Johnson Innovation,” the company said.
Without providing financial details, Johnson & Johnson said the deals include investments, out-licensing and strategic deals.
Among others, Janssen Pharmaceuticals is collaborating with Bird Rock Bio on a CB1-targeting antibody, namacizumab in phase 1 study as promising treatment for non alcoholic fatty liver disease, or NASH. The unit is also collaborating with Amorsa Therapeutics on the development of new antidepressants with rapid onset of action for patients with treatment-resistant depression.